Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05413850
Phase: Phase 1|Phase 2
Trial Summary: To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Blue Earth Therapeutics Ltd
Acronym:

Pin It on Pinterest